Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model Maurizio VialeMarta RossiMattia Rocco PRECLINICAL STUDIES 07 October 2015 Pages: 1151 - 1161
Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro Matthew TrendowskiTimothy D. ChristenThomas P. Fondy PRECLINICAL STUDIES Open access 22 October 2015 Pages: 1162 - 1174
Identification of a novel compound (β-sesquiphellandrene) from turmeric (Curcuma longa) with anticancer potential: comparison with curcumin Amit Kumar TyagiSahdeo PrasadBharat B. Aggarwal PRECLINICAL STUDIES 02 November 2015 Pages: 1175 - 1186
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin Jhanelle E. GrayJeffrey R. InfanteHoward A. Burris III PHASE I STUDIES 25 September 2015 Pages: 1187 - 1196
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer R. van der NollW. M. SmitJ. H. M. Schellens PHASE I STUDIES Open access 11 September 2015 Pages: 1197 - 1205
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors Sandrine J. FaivreAnthony J. OlszanskiEric Raymond PHASE I STUDIES 16 September 2015 Pages: 1206 - 1216
A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort Theresa L. WernerMark L. WadeSunil Sharma PHASE I STUDIES 14 September 2015 Pages: 1217 - 1224
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors Autumn J. McReeHanna K. SanoffBert H. O’Neil PHASE I STUDIES 21 October 2015 Pages: 1225 - 1231
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies Åke BerglundAnders UllénJoachim Gullbo PHASE I STUDIES 10 November 2015 Pages: 1232 - 1241
Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients J. M. BaasL. L. KrensH. J. Guchelaar PHASE II STUDIES Open access 19 September 2015 Pages: 1242 - 1247
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer Paul L. SwiecickiLili ZhaoFrancis P. Worden PHASE II STUDIES 10 October 2015 Pages: 1248 - 1256
Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma Sadahisa OgasawaraTetsuhiro ChibaOsamu Yokosuka SHORT REPORT 14 October 2015 Pages: 1257 - 1262
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients François GhiringhelliJulie VincentSylvain Ladoire SHORT REPORT 22 October 2015 Pages: 1263 - 1266
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation Pierre CombeLaure ChauvenetEric Pujade-Lauraine SHORT REPORT 21 October 2015 Pages: 1267 - 1270
Blinatumomab for the treatment of acute lymphoblastic leukemia Jason B. KaplanMarina GrischenkoFrancis J. Giles REVIEW 17 September 2015 Pages: 1271 - 1279
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies Diana MarkozashviliVincent RibragYegor S. Vassetzky REVIEW 30 September 2015 Pages: 1280 - 1291
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors Geoffrey I. ShapiroStewart McCallumPatricia LoRusso Erratum 26 September 2015 Pages: 1292 - 1292
